Full Press Release Details
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
Completed $72.5 million PIPE financing extending cash runway into 2025
PRECISION 1 trial on-track with preliminary data expected in the first half of 2023
24% revenue growth of FYARRO (nab-sirolimus) over the second quarter 2022
Appointment of Neil Desai to Executive Chairman and transition of Brendan Delaney to CEO effective January 1, 2023
Conference call to be held today at 8:30 am ET
LOS ANGELES, CA, November 9, 2022 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing
precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the third quarter of 2022.
The last several months have been transformational for Aadi, most recently having strengthened our balance sheet with a $72.5 million PIPE
financing. In addition, we saw continued progress in patient enrollment for the PRECISION 1 trial targeting TSC1 and TSC2 inactivating alterations, and we anticipate providing preliminary data on a meaningful number of patients from
PRECISION 1 in the first half of 2023, said Neil Desai, Ph.D., Founder and Chief Executive Officer of Aadi. We also expanded our pipeline through the recent clinical collaboration with Mirati to explore the combination of
nab-sirolimus with the KRAS inhibitor adagrasib, which we believe could potentially overcome tumor resistance.
progress in the last year, positioning us well for the next phase of growth. In preparation for the advancements to come, we are also realigning our management structure. We announced last evening that I am moving into the role of Executive Chairman
while our current COO, Brendan Delaney, will transition to President and CEO, continued Desai. Brendan s proven expertise, committed leadership and broad strategic vision have been key drivers of our success. Going forward, Brendan
will assume leadership of the Company while my personal focus will turn toward advancement of our scientific initiatives.
Brendan Delaney, current
Chief Operating Officer of Aadi commented, It s such an exciting time at Aadi, and I couldn t be more pleased with the execution our team has demonstrated. I am honored to have been selected to lead this organization as we move
forward and execute on the strategies that will support further growth. Our oncology franchise is growing, and I believe we are well-positioned to achieve our goal of becoming a leading precision oncology company that delivers on providing
therapeutic benefit to patients in need.
Corporate Updates for the Third Quarter 2022 and Recent Highlights
Third Quarter 2022 Financial Results
Conference Call Information
The Aadi management team is hosting a conference call and webcast today at 8:30 am ET (5:30 am PT) to provide a corporate update and discuss results for the
third quarter of 2022.
Participants may access a live webcast of the call on the Investors & News page of the Aadi Biosciences
website at aadibio.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company s website for at least 30 days.
FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid
cell tumor (PEComa).
About the PRECISION 1 Trial
The PRECISION 1 trial is a multi-center, open-label, tumor-agnostic pivotal study, of nab-sirolimus designed as a basket trial that will evaluate
approximately 120 adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. The trial will have two independent arms of 60 patients each to separately evaluate patients with
either TSC1 or TSC2 inactivating alterations. Aadi has received Fast Track designation to evaluate nab-sirolimus in this indication from the FDA. The first patient in the PRECISION 1 trial was dosed in March 2022.
About Aadi Bioscience
Aadi is a commercial-stage
biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November of 2021 and in February of
2022 commercialized FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-na ve
malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company s development pipeline is available on the Aadi website at www.aadibio.com and connect
with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the business of Aadi Biosciences that are not a description of historical facts within
the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company s current beliefs and expectations; the Company s anticipated growth; plans and potential for success
relating to commercializing FYARRO; expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO; expectations regarding management s performance; plans related to further development and
manufacturing of FYARRO; pricing and reimbursement of FYARRO; the rate and degree of market acceptance of FYARRO; anticipated reception of FYARRO in the physician community; the clinical results and timing of additional clinical trials, including
the registration-directed
trial in patients harboring TSC1 or TSC2 inactivating alterations; the timing and likelihood of regulatory filings and approvals of FYARRO, including in potential additional
indications and potential filings in additional jurisdictions; plans regarding clinical trials, in collaboration with Mirati Therapeutics, for the combination of adagrasib and nab-sirolimus in patients with KRASG12C-mutant tumors and related timing
and expectations regarding the efficacy of the combination; and the sufficiency of our existing capital resources and the expected timeframe to fund our future operating expenses and capital expenditure requirements. Actual results could differ
materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those associated with the ability to successfully commercialize FYARRO; risks related to
reimbursement and pricing of FYARRO; uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for
additional indications; the risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO; risks associated with the failure to realize any value from FYARRO in light of inherent
risks and difficulties involved in successfully bringing product candidates to market; risks related to Aadi s estimates regarding future expenses, capital requirements and need for additional financing; and risks related to the impact of the COVID-19 pandemic on Aadi s operations, the biotechnology industry and the economy generally.
Additional risks and
uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company s Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, including under the caption Item 1A. Risk Factors, and in Aadi s subsequent Quarterly Reports on Form 10-Q filed on May 12, 2022, August 10,
2022 and November 9, 2022, and elsewhere in Aadi s reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no
obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this
cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
AADI BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 134,815 | $ | 148,989 | ||||
| Short-term investments | 48,192 | |||||||
| Accounts receivable, net | 2,261 | |||||||
| Inventory | 734 | |||||||
| Prepaid expenses and other current assets | 3,861 | 2,283 | ||||||
| Total current assets | 189,863 | 151,272 | ||||||
| Property and equipment, net | 457 | 57 | ||||||
| Operating lease right-of-use assets | 1,573 | 557 | ||||||
| Intangible asset, net | 3,811 | |||||||
| Other assets | 2,210 | 2,213 | ||||||
| Total assets | $ | 194,103 | $ | 157,910 | ||||
| Liabilities and stockholders equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,920 | $ | 6,439 | ||||
| Accrued liabilities | 13,597 | 8,703 | ||||||
| Operating lease liabilities, current portion | 374 | 131 | ||||||
| Total current liabilities | 17,891 | 15,273 | ||||||
| Operating lease liabilities, net of current portion | 1,347 | 474 | ||||||
| Due to licensor | 5,757 | 5,757 | ||||||
| Total liabilities | 24,995 | 21,504 | ||||||
| Stockholders equity: | ||||||||
| Preferred stock | ||||||||
| Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 358,490 | 279,089 | ||||||
| Accumulated other comprehensive loss | (99 | ) | ||||||
| Accumulated deficit | (189,285 | ) | (142,685 | ) | ||||
| Total stockholders equity | 169,108 | 136,406 | ||||||
| Total liabilities and stockholders equity | $ | 194,103 | $ | 157,910 |
AADI BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except shares and earnings per share amounts)
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | ||||||||||||||||
| Product sales, net | $ | 4,245 | $ | $ | 9,989 | $ | ||||||||||
| Grant revenue | 120 | |||||||||||||||
| Total Revenue | 4,245 | 9,989 | 120 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 9,915 | 7,401 | 29,069 | 8,793 | ||||||||||||
| Research and development | 8,773 | 5,754 | 23,292 | 12,443 | ||||||||||||
| Cost of goods sold | 593 | 1,113 | ||||||||||||||
| Impairment of intangible asset | 74,156 | 3,724 | 74,156 | |||||||||||||
| Total operating expenses | 19,281 | 87,311 | 57,198 | 95,392 | ||||||||||||
| Loss from operations | (15,036 | ) | (87,311 | ) | (47,209 | ) | (95,272 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Change in fair value of convertible promissory notes | 380 | 1,585 | ||||||||||||||
| Gain upon extinguishment of debt | 196 | |||||||||||||||
| Interest income | 620 | 791 | 1 | |||||||||||||
| Interest expense | (58 | ) | (157 | ) | (173 | ) | (608 | ) | ||||||||
| Total other income, net | 562 | 223 | 618 | 1,174 | ||||||||||||
| Loss before income tax expense | (14,474 | ) | (87,088 | ) | (46,591 | ) | (94,098 | ) | ||||||||
| Income tax expense | (9 | ) | (2 | ) | ||||||||||||
| Net loss | (14,474 | ) | (87,088 | ) | (46,600 | ) | (94,100 | ) | ||||||||
| Other comprehensive loss | ||||||||||||||||
| Change in unrealized loss on short-term investments | (99 | ) | (99 | ) | ||||||||||||
| Comprehensive loss | $ | (14,573 | ) | $ | (87,088 | ) | $ | (46,699 | ) | $ | (94,100 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.68 | ) | $ | (9.17 | ) | $ | (2.21 | ) | $ | (19.37 | ) | ||||
| Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted | 21,269,163 | 9,510,379 | 21,052,786 | 4,890,556 |